These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 15037669)

  • 1. Rapid treatment of "wearing off" in Parkinson's disease.
    Swope DM
    Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Clin Neuropharmacol; 1996 Jun; 19(3):193-201. PubMed ID: 8726538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical considerations in the use of apomorphine injectable.
    Bowron A
    Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Hauser RA; LeWitt PA; Comella CL
    Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
    Simonson W; Hauser RA; Schapira AH
    Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R
    J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease--levodopa complications.
    King DB
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S13-20. PubMed ID: 10451755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-related wearing-off in Parkinson's disease: identification and management.
    Pahwa R; Lyons KE
    Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD; Chen JJ; Swope DM
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.
    Cristina S; Zangaglia R; Mancini F; Martignoni E; Nappi G; Pacchetti C
    Clin Neuropharmacol; 2003; 26(3):146-50. PubMed ID: 12782917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.